Daiichi Sankyo

Daiichi Sankyo

Company Less

Daiichi Sankyo

to get instant updates about 'Daiichi Sankyo' on your MyPage. Meet other similar minded people. Its Free!


All Updates

is the third largest pharmaceutical company in Japan and Asia and a top 16 pharmaceutical company in the world. The company has over 30,000 employees worldwide and achieved $9.7 billion USD in revenue during the 2009 fiscal year. Its headquarter is based in Tokyo and the independent subsidiaries Plexxikon and U3 Pharma are located in Berkeley, CA and Munich, respectively.


Daiichi Sankyo was established in 2005 through the merger of and , which were century-old pharmaceutical companies based in Japan.


In 2006, Daiichi Sankyo acquired Zepharma, the OTC drugs unit of Astellas Pharma.

On June 10, 2008, Daiichi Sankyo agreed to take a majority (35%) stake in Indian generic drug maker Ranbaxy, with a deal valued at about $4.6 billion.

In June 2008, Daiichi Sankyo acquired U3 Pharma, which would contribute a therapeutic anti-HER3 antibody to the company's anticancer portfolio.

On April 4, 2011 Daiichi Sankyo completed the acquisition of Plexxikon, a Berkley CA-based pharmaceutical start-up company for $805 and an additional $130 in milestone payments, pending on the success of Vemurafenib (Plexxikon’s lead program) an oral, novel drug that targets the oncogenic BRAF mutation present in about half of melanoma cancers and about eight percent of all solid tumors. Daiichi Sankyo is retaining US co-promotion right of the (GSK licensed) drug.

Products of Daiichi......

Read More

No feeds found

Posting your question. Please wait!...


No messages found
Suggested Pages
Tell your friends >
about this page
 Create a new Page
for companies, colleges, celebrities or anything you like.Get updates on MyPage.
Create a new Page
 Find your friends
  Find friends on MyPage from